GlaxoSmithKline Stock Price, News & Analysis (LON:GSK)

GBX 1,358 4.80 (0.35 %)
(As of 01/21/2018 04:00 PM ET)
Previous CloseGBX 1,358
Today's RangeGBX 1,351.40 - GBX 1,363.40
52-Week RangeGBX 1,270 - GBX 1,724.50
Volume10.11 million shs
Average Volume8.21 million shs
Market Capitalization£67.33 billion
P/E Ratio2,829.17
Dividend YieldN/A
BetaN/A

About GlaxoSmithKline (LON:GSK)

GlaxoSmithKline logoGlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines, vaccines and consumer healthcare products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. The Consumer Healthcare business develops and markets products in Wellness, Oral health, Nutrition and Skin health categories. Its product portfolio includes Adartrel, Bexsero, Daraprim and Quinvaxem. Its brands include Panadol, abreva, polident and physiogel.

Receive GSK News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceuticals
Sub-IndustryN/A
SectorHealthcare
SymbolLON:GSK
CUSIPN/A
Phone+44-20-80475000

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E Ratio2829.16666666667
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSGBX 0.48
Net IncomeN/A
Net Margins17.79%
Return on Equity461.88%
Return on Assets9.56%

Miscellaneous

EmployeesN/A
Outstanding Shares4,920,000,000

GlaxoSmithKline (LON:GSK) Frequently Asked Questions

What is GlaxoSmithKline's stock symbol?

GlaxoSmithKline trades on the London Stock Exchange (LON) under the ticker symbol "GSK."

How often does GlaxoSmithKline pay dividends? What is the dividend yield for GlaxoSmithKline?

GlaxoSmithKline announced a dividend on Wednesday, October 25th. Stockholders of record on Thursday, November 9th will be given a dividend of GBX 19 per share on Thursday, January 11th. This represents a dividend yield of 1.41%. The ex-dividend date of this dividend is Thursday, November 9th. The official announcement can be viewed at this link. View GlaxoSmithKline's Dividend History.

How were GlaxoSmithKline's earnings last quarter?

GlaxoSmithKline plc (LON:GSK) issued its quarterly earnings results on Wednesday, October, 25th. The company reported $32.50 EPS for the quarter, topping analysts' consensus estimates of $31.80 by $0.70. The company had revenue of $7.84 billion for the quarter. GlaxoSmithKline had a return on equity of 461.88% and a net margin of 17.79%. View GlaxoSmithKline's Earnings History.

Where is GlaxoSmithKline's stock going? Where will GlaxoSmithKline's stock price be in 2018?

20 equities research analysts have issued twelve-month target prices for GlaxoSmithKline's shares. Their predictions range from GBX 1,300 to GBX 1,925. On average, they expect GlaxoSmithKline's stock price to reach GBX 1,547.11 in the next twelve months. View Analyst Ratings for GlaxoSmithKline.

Who are some of GlaxoSmithKline's key competitors?

Who are GlaxoSmithKline's key executives?

GlaxoSmithKline's management team includes the folowing people:

  • Emma Walmsley, Chief Executive Officer, Executive Director (Age 47)
  • Simon Dingemans, Chief Financial Officer, Executive Director (Age 53)
  • Patrick Vallance, President - R&D, Executive Director (Age 56)
  • Roger Connor, President - Global Manufacturing & Supply
  • Luc Debruyne, President - Global Vaccines
  • Abbas Hussain, President - Global Pharmaceuticals
  • Shah Abbas Hussain, President - Global Pharmaceuticals
  • Brian McNamara, Chief Executive Officer - GSK Consumer Healthcare (Age 50)
  • Luke Miels, President - Global Pharmaceuticals
  • Daniel E. Troy, Senior Vice President, General Counsel

How do I buy GlaxoSmithKline stock?

Shares of GlaxoSmithKline and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is GlaxoSmithKline's stock price today?

One share of GlaxoSmithKline stock can currently be purchased for approximately GBX 1,358.

How big of a company is GlaxoSmithKline?

GlaxoSmithKline has a market capitalization of £67.33 billion.

How can I contact GlaxoSmithKline?

GlaxoSmithKline's mailing address is 980 Great West Road, BRENTFORD, TW8 9GS, United Kingdom. The company can be reached via phone at +44-20-80475000.


MarketBeat Community Rating for GlaxoSmithKline (GSK)

Community Ranking:  1.5 out of 5 (star half star)
Outperform Votes:  547 (Vote Outperform)
Underperform Votes:  1,223 (Vote Underperform)
Total Votes:  1,770
MarketBeat's community ratings are surveys of what our community members think about GlaxoSmithKline and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

GlaxoSmithKline (LON:GSK) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.202.152.112.14
Ratings Breakdown: 3 Sell Rating(s)
10 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
3 Sell Rating(s)
11 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
9 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
4 Sell Rating(s)
11 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: GBX 1,547.11GBX 1,544.47GBX 1,663.89GBX 1,727.81

GlaxoSmithKline (LON:GSK) Consensus Price Target History

Price Target History for GlaxoSmithKline (LON:GSK)

GlaxoSmithKline (LON:GSK) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetDetails
1/17/2018BarclaysUpgradeOverweightGBX 1,450 -> GBX 1,650View Rating Details
1/16/2018Jefferies GroupReiterated RatingBuyGBX 1,500View Rating Details
1/16/2018BNP ParibasReiterated RatingNeutralGBX 1,580View Rating Details
1/15/2018Liberum CapitalReiterated RatingBuyGBX 1,760View Rating Details
1/11/2018Deutsche BankBoost Price TargetHoldGBX 1,380 -> GBX 1,440View Rating Details
1/4/2018JPMorgan Chase & Co.Set Price TargetNeutralGBX 1,340View Rating Details
12/13/2017Berenberg BankReiterated RatingBuyGBX 1,760View Rating Details
12/13/2017CitigroupReiterated RatingNeutralGBX 1,400View Rating Details
12/6/2017Bank of AmericaSet Price TargetNeutralGBX 1,450View Rating Details
12/1/2017Morgan StanleyLower Price TargetUnderweightGBX 1,450 -> GBX 1,400View Rating Details
12/1/2017Goldman Sachs GroupSet Price TargetBuyGBX 1,775View Rating Details
11/30/2017Shore CapitalReiterated RatingHoldView Rating Details
11/22/2017HSBCReiterated RatingBuyGBX 1,925View Rating Details
11/6/2017InvestecDowngradeHoldGBX 1,800 -> GBX 1,390View Rating Details
11/9/2017Societe GeneraleReiterated RatingSellView Rating Details
11/8/2017Beaufort SecuritiesLower Price TargetBuyGBX 1,800 -> GBX 1,450View Rating Details
11/1/2017Kepler Capital MarketsLower Price TargetReduceGBX 1,520 -> GBX 1,340View Rating Details
10/26/2017S&P GlobalSet Price TargetNeutralGBX 1,500View Rating Details
9/19/2017Bryan, Garnier & CoReiterated RatingNeutralGBX 1,710View Rating Details
9/6/2017Credit Suisse GroupLower Price TargetNeutralGBX 1,775 -> GBX 1,725View Rating Details
10/27/2016NatixisReiterated RatingNeutralGBX 1,750View Rating Details
10/19/2016Sanford C. BernsteinSet Price TargetNeutralGBX 1,834View Rating Details
8/4/2016Independent ResearchSet Price TargetNeutralGBX 1,800View Rating Details
7/27/2016S&P GlobalSet Price TargetNeutralGBX 1,650View Rating Details
7/7/2016Canaccord GenuityReiterated RatingHoldGBX 1,785View Rating Details
3/10/2016AlphaValueReiterated RatingAddGBX 1,536View Rating Details
2/12/2016Baader BankReiterated RatingHoldGBX 1,530View Rating Details
1/28/2016Leerink SwannReiterated RatingMarket PerformGBX 1,565View Rating Details
(Data available from 1/21/2016 forward)

Earnings

GlaxoSmithKline (LON:GSK) Earnings History and Estimates Chart

Earnings by Quarter for GlaxoSmithKline (LON:GSK)

GlaxoSmithKline (LON GSK) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/25/2017Q3 2017GBX 31.80GBX 32.50GBX 784.30 billionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

GlaxoSmithKline (LON:GSK) Earnings Estimates

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

GlaxoSmithKline (LON:GSK) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/25/2017GBX 191.41%11/9/201711/9/20171/11/2018
7/26/2017GBX 191.23%8/10/20178/10/201710/12/2017
4/26/2017GBX 191.21%5/11/20175/11/20177/13/2017
2/8/2017GBX 231.47%2/23/20172/23/20174/13/2017
10/26/2016GBX 191.17%11/3/201611/3/20161/12/2017
7/27/2016GBX 191.12%8/11/20168/11/201610/13/2016
4/27/2016GBX 191.28%5/12/20165/12/20167/14/2016
10/28/2015GBX 191.34%11/12/201511/12/20151/14/2016
10/28/2015GBX 201.34%2/18/20162/18/20164/14/2016
7/29/2015GBX 191.38%8/13/20158/13/201510/1/2015
5/6/2015GBX 191.25%5/14/20155/14/20157/9/2015
2/4/2015GBX 231.56%2/19/20152/19/20154/9/2015
10/22/2014GBX 191.37%11/6/201411/6/20141/8/2015
7/23/2014GBX 191.28%8/6/20148/6/201410/2/2014
4/30/2014GBX 191.17%5/14/20145/14/20147/10/2014
2/5/2014GBX 231.36%2/19/20142/19/20144/10/2014
10/23/2013GBX 191.15%11/13/201311/13/20131/9/2014
(Data available from 1/1/2013 forward)

Insider Trades

GlaxoSmithKline (LON GSK) Insider Trading and Institutional Ownership History

Insider Trades by Quarter for GlaxoSmithKline (LON:GSK)

GlaxoSmithKline (LON GSK) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/10/2018Dominic RedfernInsiderBuy10GBX 1,333£133.30
12/18/2017Patrick VallanceInsiderSell20,000GBX 1,310£262,000
12/11/2017Dominic RedfernInsiderBuy9GBX 1,302£117.18
11/9/2017Patrick VallanceInsiderBuy10GBX 1,364£136.40
10/25/2017Urs RohnerInsiderBuy473GBX 1,518£7,180.14
10/12/2017Simon DingemansInsiderBuy1,076GBX 1,527£16,430.52
10/10/2017Victoria WhyteInsiderBuy9GBX 1,518£136.62
9/11/2017Dominic RedfernInsiderBuy8GBX 1,501£120.08
8/9/2017Dominic RedfernInsiderBuy8GBX 1,519£121.52
7/26/2017Manvinder Singh BangaInsiderBuy2,267GBX 1,599£36,249.33
7/14/2017Patrick VallanceInsiderBuy861GBX 1,618£13,930.98
7/11/2017Victoria WhyteInsiderBuy8GBX 1,604£128.32
6/20/2017Victoria WhyteInsiderSell4,820GBX 1,693£81,602.60
6/9/2017Simon DingemansInsiderBuy7GBX 1,701£119.07
5/10/2017Patrick VallanceInsiderBuy7GBX 1,615£113.05
4/26/2017Vivienne CoxInsiderBuy335GBX 1,583£5,303.05
4/18/2017Emma WalmsleyInsiderBuy83GBX 1,647£1,367.01
4/13/2017Dominic RedfernInsiderBuy230GBX 1,639£3,769.70
3/9/2017Sir Andrew P WittyInsiderBuy7GBX 1,673£117.11
3/7/2017Moncef SlaouiInsiderBuy56GBX 2,072£1,160.32
2/22/2017Simon DingemansInsiderSell3,589GBX 1,640£58,859.60
2/20/2017Sir Andrew P WittyInsiderSell10,633GBX 1,634£173,743.22
2/16/2017Patrick VallanceInsiderSell32,996GBX 1,624£535,855.04
2/9/2017Victoria WhyteInsiderSell4,820GBX 1,576£75,963.20
2/8/2017Vivienne CoxInsiderBuy342GBX 1,555£5,318.10
1/11/2017Simon DingemansInsiderBuy8GBX 1,596£127.68
1/9/2017Moncef SlaouiInsiderBuy58GBX 1,972£1,143.76
12/9/2016Sir Andrew P WittyInsiderBuy8GBX 1,478£118.24
11/9/2016Victoria WhyteInsiderBuy8GBX 1,593£127.44
11/3/2016Moncef SlaouiInsiderBuy6GBX 1,937£116.22
10/27/2016Sir Andrew P WittyInsiderSell10,000GBX 1,636£163,600
10/26/2016Manvinder Singh BangaInsiderBuy1,750GBX 1,643£28,752.50
10/11/2016Simon DingemansInsiderBuy7GBX 1,728£120.96
10/7/2016Moncef SlaouiInsiderBuy4GBX 2,148GBX 8,592
9/22/2016Moncef SlaouiInsiderBuy2GBX 2,179GBX 4,358
9/9/2016Witty,Sir Andrew PInsiderBuy8GBX 1,616£129.28
8/12/2016Slaoui,MoncefInsiderBuy28GBX 2,208£618.24
8/9/2016Dingemans,SimonInsiderBuy8GBX 1,680£134.40
7/27/2016Witty,Sir Andrew PInsiderSell10,000GBX 1,693£169,300
7/11/2016Witty,Sir Andrew PInsiderBuy7GBX 1,671£116.97
7/8/2016Slaoui,MoncefInsiderBuy4GBX 2,169GBX 8,676
7/1/2016Cartwright,StaceyInsiderBuy461GBX 1,559£7,186.99
6/9/2016Dingemans,SimonInsiderBuy9GBX 1,441£129.69
5/20/2016Slaoui,MoncefInsiderBuy14GBX 2,100£294
5/12/2016Slaoui,MoncefInsiderBuy24GBX 2,103£504.72
5/11/2016Witty,Sir Andrew PInsiderBuy8GBX 1,476£118.08
4/28/2016Witty,Sir Andrew PInsiderSell10,000GBX 1,475£147,500
4/14/2016Slaoui,MoncefInsiderBuy495GBX 2,156£10,672.20
3/31/2016Anderson,Sir RoyInsiderBuy511GBX 1,405£7,179.55
3/9/2016Witty,Sir Andrew PInsiderBuy9GBX 1,404£126.36
2/15/2016Dingemans,SimonInsiderSell39,987GBX 1,406£562,217.22
2/9/2016Witty,Sir Andrew PInsiderBuy9GBX 1,369£123.21
1/28/2016Dingemans,SimonInsiderBuy684GBX 1,381£9,446.04
1/14/2016Witty,Sir Andrew PInsiderBuy43GBX 1,369£588.67
1/12/2016Dingemans,SimonInsiderBuy9GBX 1,359£122.31
12/9/2015Dingemans,SimonInsiderBuy9GBX 1,325£119.25
11/10/2015Dingemans,SimonInsiderBuy9GBX 1,366£122.94
10/12/2015Dingemans,SimonInsiderBuy10GBX 1,307£130.70
10/1/2015Rohner,UrsInsiderBuy525GBX 1,251£6,567.75
9/10/2015Witty,Sir Andrew PInsiderBuy10GBX 1,318£131.80
8/12/2015Dingemans,SimonInsiderBuy8GBX 1,443£115.44
7/10/2015Witty,Sir Andrew PInsiderBuy9GBX 1,369£123.21
7/1/2015Wijers,HansInsiderBuy534GBX 13.45GBX 7,182.30
3/31/2015Sir Christopher GentInsiderBuy3,991GBX 1,566£62,499.06
3/9/2015Moncef SlaouiInsiderSell22,274GBX 1,544£343,910.56
2/18/2015Moncef SlaouiInsiderSell1,580GBX 1,553£24,537.40
2/13/2015Simon DingemansInsiderSell12,605GBX 1,543.12£194,510.28
(Data available from 1/1/2013 forward)

Headlines

GlaxoSmithKline (LON GSK) News Headlines

Source:
DateHeadline
GlaxoSmithKline plc (GSK) Receives Average Recommendation of "Hold" from BrokeragesGlaxoSmithKline plc (GSK) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 20 at 6:16 AM
NeuroMetrixs stock soars in active trade after collaboration with GlaxoSmithKline on QuellNeuroMetrix's stock soars in active trade after collaboration with GlaxoSmithKline on Quell
finance.yahoo.com - January 17 at 9:40 AM
Glaxo CEO Walmsleys Shakeup Continues With Job Cuts in AfricaGlaxo CEO Walmsley's Shakeup Continues With Job Cuts in Africa
finance.yahoo.com - January 17 at 9:40 AM
Glaxos Influenza Vaccine Gets FDA Nod for Label ExpansionGlaxo's Influenza Vaccine Gets FDA Nod for Label Expansion
finance.yahoo.com - January 15 at 9:42 AM
GSK receives FDA approval for expanded indication for FLUARIX® QUADRIVALENT (Influenza Vaccine) for persons 6 months and olderGSK receives FDA approval for expanded indication for FLUARIX® QUADRIVALENT (Influenza Vaccine) for persons 6 months and older
finance.yahoo.com - January 12 at 9:51 AM
Insider Buying: GlaxoSmithKline plc (GSK) Insider Acquires 10 Shares of StockInsider Buying: GlaxoSmithKline plc (GSK) Insider Acquires 10 Shares of Stock
www.americanbankingnews.com - January 11 at 12:32 PM
Deutsche Bank Raises GlaxoSmithKline (GSK) Price Target to GBX 1,440Deutsche Bank Raises GlaxoSmithKline (GSK) Price Target to GBX 1,440
www.americanbankingnews.com - January 11 at 6:46 AM
What Should We Expect From GlaxoSmithKline plc’s (LON:GSK) Earnings In The Years Ahead?What Should We Expect From GlaxoSmithKline plc’s (LON:GSK) Earnings In The Years Ahead?
finance.yahoo.com - January 9 at 9:47 AM
Why GlaxoSmithKline plc shares could be the buy of the decadeWhy GlaxoSmithKline plc shares could be the buy of the decade
www.fool.co.uk - January 6 at 9:46 AM
Paul Stead Joins Adaptimmune as Vice President of Business DevelopmentPaul Stead Joins Adaptimmune as Vice President of Business Development
finance.yahoo.com - January 4 at 9:44 AM
JPMorgan Chase & Co. Reaffirms Neutral Rating for GlaxoSmithKline (GSK)JPMorgan Chase & Co. Reaffirms Neutral Rating for GlaxoSmithKline (GSK)
www.americanbankingnews.com - December 30 at 10:26 PM
GlaxoSmithKline (GSK) Given a GBX 1,775 Price Target at Goldman Sachs GroupGlaxoSmithKline (GSK) Given a GBX 1,775 Price Target at Goldman Sachs Group
www.americanbankingnews.com - December 30 at 7:24 PM
GlaxoSmithKline (GSK) PT Set at GBX 1,340 by JPMorgan Chase & Co.GlaxoSmithKline (GSK) PT Set at GBX 1,340 by JPMorgan Chase & Co.
www.americanbankingnews.com - December 29 at 2:50 PM
GlaxoSmithKline plc (GSK) Given Average Rating of "Hold" by BrokeragesGlaxoSmithKline plc (GSK) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 26 at 6:48 AM
GlaxoSmithKline: Dividend Risk Brings Opportunity - Seeking AlphaGlaxoSmithKline: Dividend Risk Brings Opportunity - Seeking Alpha
seekingalpha.com - December 19 at 5:03 PM
Insider Selling: GlaxoSmithKline plc (GSK) Insider Sells 20,000 Shares of StockInsider Selling: GlaxoSmithKline plc (GSK) Insider Sells 20,000 Shares of Stock
www.americanbankingnews.com - December 18 at 5:26 PM
GlaxoSmithKline boosts stake in Saudi Arabia unitGlaxoSmithKline boosts stake in Saudi Arabia unit
finance.yahoo.com - December 18 at 10:06 AM
GlaxoSmithKline (GSK) Earns Neutral Rating from J P Morgan Chase & CoGlaxoSmithKline (GSK) Earns Neutral Rating from J P Morgan Chase & Co
www.americanbankingnews.com - December 17 at 2:28 PM
GlaxoSmithKline (GSK) Earns Neutral Rating from CitigroupGlaxoSmithKline (GSK) Earns Neutral Rating from Citigroup
www.americanbankingnews.com - December 17 at 12:50 PM
10 Biggest Antidepressant Drug Companies In 201710 Biggest Antidepressant Drug Companies In 2017
finance.yahoo.com - December 14 at 9:54 AM
GlaxoSmithKline (GSK) Given a GBX 1,550 Price Target by UBS AnalystsGlaxoSmithKline (GSK) Given a GBX 1,550 Price Target by UBS Analysts
www.americanbankingnews.com - December 13 at 7:34 PM
GlaxoSmithKline (GSK) Earns Buy Rating from Berenberg BankGlaxoSmithKline (GSK) Earns Buy Rating from Berenberg Bank
www.americanbankingnews.com - December 13 at 4:46 PM
ADRO Dumps CRS-207, Another Win For CoolSculpting, FDA Expands GSKs Nucala UseADRO Dumps CRS-207, Another Win For CoolSculpting, FDA Expands GSK's Nucala Use
www.nasdaq.com - December 13 at 10:05 AM
Form 6-K GLAXOSMITHKLINE PLC For: Dec 12 - StreetInsider.comForm 6-K GLAXOSMITHKLINE PLC For: Dec 12 - StreetInsider.com
www.streetinsider.com - December 12 at 5:30 PM
GlaxoSmithKline plc (GSK) Insider Buys £117.18 in StockGlaxoSmithKline plc (GSK) Insider Buys £117.18 in Stock
www.americanbankingnews.com - December 12 at 2:58 PM
Glaxos New Pharma Head Looks to Move Fast, Especially in CancerGlaxo's New Pharma Head Looks to Move Fast, Especially in Cancer
finance.yahoo.com - December 11 at 10:30 AM
GSKs Shingrix effective in phase 3 studyGSK's Shingrix effective in phase 3 study
www.marketwatch.com - December 7 at 10:04 AM
Oversold Conditions For GlaxoSmithKline (GSK)Oversold Conditions For GlaxoSmithKline (GSK)
www.nasdaq.com - December 7 at 10:04 AM
Bank of America Analysts Give GlaxoSmithKline (GSK) a GBX 1,450 Price TargetBank of America Analysts Give GlaxoSmithKline (GSK) a GBX 1,450 Price Target
www.americanbankingnews.com - December 6 at 7:11 PM
GlaxoSmithKline’s Vaccines Business in 3Q17GlaxoSmithKline’s Vaccines Business in 3Q17
finance.yahoo.com - December 6 at 9:57 AM
GlaxoSmithKline’s HIV Business in 3Q17GlaxoSmithKline’s HIV Business in 3Q17
finance.yahoo.com - December 5 at 10:29 AM
Investors Are Undervaluing GlaxoSmithKline plc (LSE:GSK) By 32.79%, Here Is My Intrinsic Value CalculationInvestors Are Undervaluing GlaxoSmithKline plc (LSE:GSK) By 32.79%, Here Is My Intrinsic Value Calculation
finance.yahoo.com - December 5 at 10:29 AM
GlaxoSmithKline’s Quarterly Revenues for 3Q17GlaxoSmithKline’s Quarterly Revenues for 3Q17
finance.yahoo.com - December 4 at 9:47 AM
Glaxo Begins Phase III Study on Injection to Prevent HIV - NasdaqGlaxo Begins Phase III Study on Injection to Prevent HIV - Nasdaq
www.nasdaq.com - December 1 at 5:07 PM
GlaxoSmithKline plc (GSK) Receives Consensus Recommendation of "Hold" from BrokeragesGlaxoSmithKline plc (GSK) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - December 1 at 10:06 AM
GlaxoSmithKline (GSK) Price Target Cut to GBX 1,400 by Analysts at Morgan StanleyGlaxoSmithKline (GSK) Price Target Cut to GBX 1,400 by Analysts at Morgan Stanley
www.americanbankingnews.com - December 1 at 6:12 AM
GlaxoSmithKline (GSK) Earns "Hold" Rating from Shore CapitalGlaxoSmithKline (GSK) Earns "Hold" Rating from Shore Capital
www.americanbankingnews.com - November 30 at 9:42 PM
Glaxo Stock Down So Far This Year: Is a Reversal in Store?Glaxo Stock Down So Far This Year: Is a Reversal in Store?
finance.yahoo.com - November 30 at 10:16 AM
Glaxo Submits NDA for Anti Relapse Malaria Medicine to FDA ... - NasdaqGlaxo Submits NDA for Anti Relapse Malaria Medicine to FDA ... - Nasdaq
www.nasdaq.com - November 29 at 5:24 PM
GlaxoSmithKline plc (GSK) PT Set at GBX 1,550 by UBS AGGlaxoSmithKline plc (GSK) PT Set at GBX 1,550 by UBS AG
www.americanbankingnews.com - November 27 at 9:04 AM
Glaxo (GSK) Files for US Label Expansion of COPD Inhaler - NasdaqGlaxo (GSK) Files for US Label Expansion of COPD Inhaler - Nasdaq
www.nasdaq.com - November 24 at 4:45 PM
Metrics for Quant Score Make GlaxoSmithKline (GSK) a Sell - Investorplace.comMetrics for Quant Score Make GlaxoSmithKline (GSK) a Sell - Investorplace.com
investorplace.com - November 24 at 4:45 PM
GlaxoSmithKline plc (GSK) Receives Buy Rating from HSBC Holdings PLCGlaxoSmithKline plc (GSK) Receives Buy Rating from HSBC Holdings PLC
www.americanbankingnews.com - November 23 at 10:40 PM
GlaxoSmithKline plc (GSK) Rating Reiterated by Shore CapitalGlaxoSmithKline plc (GSK) Rating Reiterated by Shore Capital
www.americanbankingnews.com - November 22 at 9:29 PM
UPDATE 1-US FDA approves first two-drug HIV regimen from GSK - ReutersUPDATE 1-US FDA approves first two-drug HIV regimen from GSK - Reuters
www.reuters.com - November 22 at 12:32 AM
Juluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infectionJuluca® (dolutegravir and rilpivirine) approved in US as first 2-drug regimen, once-daily, single pill - a complete regimen for the maintenance treatment of virologically suppressed HIV-1 infection
finance.yahoo.com - November 22 at 12:32 AM
GlaxoSmithKline plc (GSK) Lowered to "Hold" at InvestecGlaxoSmithKline plc (GSK) Lowered to "Hold" at Investec
www.americanbankingnews.com - November 19 at 12:58 PM
Jefferies Group LLC Cuts GlaxoSmithKline plc (GSK) Price Target to GBX 1,450Jefferies Group LLC Cuts GlaxoSmithKline plc (GSK) Price Target to GBX 1,450
www.americanbankingnews.com - November 19 at 12:16 AM
Theravance Shares Rise on Approval of Glaxos COPD TherapyTheravance Shares Rise on Approval of Glaxo's COPD Therapy
finance.yahoo.com - November 17 at 5:53 PM
Glaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EUGlaxo's Triple Therapy COPD Inhaler Gets Marketing Nod in EU
finance.yahoo.com - November 17 at 5:53 PM

SEC Filings

GlaxoSmithKline (LON:GSK) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Social activity is not available for this stock.

Financials

Financials are not available for this stock.

Chart

GlaxoSmithKline (LON GSK) Stock Chart for Sunday, January, 21, 2018

Loading chart…

This page was last updated on 1/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.